Shares fell after the company cut its full-year guidance on the back of challenging macroeconomic conditions and ...

Germany's Merck KGaA shares plunged after the company slashed its full-year outlook on the back of uncertainty around tariffs and foreign-exchange headwinds. In European morning trading shares were ...

Merck KGaA reduced its outlook for sales and profit growth this year, citing the impact of a weak US dollar and uncertainty ...

German pharmaceutical and specialty materials group Merck KGaA on Thursday guided more cautiously for 2025 earnings, citing ...

The U.S. Food and Drug Administration (FDA) on Wednesday approved Merck & Co. Inc.’s (NYSE:MRK) Welireg (belzutifan) for ...

Merck has received approval from the Food and Drug Administration for Welireg, its oral inhibitor for patients with certain rare types of neuroendocrine tumors. The company said Wednesday the ...

The latest health news highlights Sanofi's $20 billion U.S. investment through 2030, Merck's cancer drug expansion and the ...

Find insight on Merck and Exelixis in the latest Market Talks covering Health Care.

The treatment, branded as Emrelis, belongs to a class of drugs known as antibody-drug conjugates, which act as ...

The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a ...

Merck (MRK) stock in focus as the FDA approves its anticancer agent Welireg for two rare neuroendocrine tumors, expanding its ...